329 related articles for article (PubMed ID: 32752582)
1. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
Guo MZ; Marrone KA; Spira A; Scott SC
Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
6. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
8. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA damage in SCLC.
Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.
Wang X; Zeng X; Li D; Zhu C; Guo X; Feng L; Yu Z
Biomed Pharmacother; 2022 Sep; 153():113458. PubMed ID: 36076571
[TBL] [Abstract][Full Text] [Related]
11. Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y; Chen K; Fan Y
Int J Cancer; 2023 Jun; 152(11):2243-2256. PubMed ID: 36346100
[TBL] [Abstract][Full Text] [Related]
12. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
Zhang N; Gao Y; Huang Z; Dai P; Luo Y; Wu Q; Jiang X; Sun W; Zhang J; Han L; Zhang J; Gong Y; Xie C
Cancer Lett; 2022 Oct; 545():215852. PubMed ID: 35926817
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer].
Huang B; Duan Y
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443
[TBL] [Abstract][Full Text] [Related]
15. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.
Cao GZ; Ma LY; Zhang ZH; Wang XL; Hua JH; Zhang JH; Lv Y; Zhang SB; Ou J; Lin WC
Acta Pharmacol Sin; 2023 Apr; 44(4):841-852. PubMed ID: 36253561
[TBL] [Abstract][Full Text] [Related]
16. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
17. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutic Options for Small Cell Lung Cancer.
Canova S; Trevisan B; Abbate MI; Colonese F; Sala L; Baggi A; Bianchi SP; D'Agostino A; Cortinovis DL
Curr Oncol Rep; 2023 Nov; 25(11):1277-1294. PubMed ID: 37870696
[TBL] [Abstract][Full Text] [Related]
19. Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.
McNamee N; da Silva IP; Nagrial A; Gao B
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175833
[TBL] [Abstract][Full Text] [Related]
20. Target engagement imaging of PARP inhibitors in small-cell lung cancer.
Carney B; Kossatz S; Lok BH; Schneeberger V; Gangangari KK; Pillarsetty NVK; Weber WA; Rudin CM; Poirier JT; Reiner T
Nat Commun; 2018 Jan; 9(1):176. PubMed ID: 29330466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]